Sedastart 1 mg/ml solution for injection for cats and dogs

Χώρα: Ιρλανδία

Γλώσσα: Αγγλικά

Πηγή: HPRA (Health Products Regulatory Authority)

Δραστική ουσία:

Medetomidine hydrochloride

Διαθέσιμο από:

Le Vet BV

Φαρμακολογική κατηγορία (ATC):

QN05CM91

INN (Διεθνής Όνομα):

Medetomidine hydrochloride

Δοσολογία:

1 milligram(s)/millilitre

Φαρμακοτεχνική μορφή:

Solution for injection

Τρόπος διάθεσης:

POM: Prescription Only Medicine as defined in relevant national legislation

Θεραπευτική ομάδα:

Cats, Dogs

Θεραπευτική περιοχή:

medetomidine

Θεραπευτικές ενδείξεις:

Neurological Preparations

Καθεστώς αδειοδότησης:

Authorised

Ημερομηνία της άδειας:

2010-04-23

Αρχείο Π.Χ.Π.

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Sedastart 1 mg/ml solution for injection for cats and dogs
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
1 ml solution for injection contains:
_Active substance:_
Medetomidine hydrochloride
1.0 mg
(equivalent to 0.85 mg medetomidine)
_Excipients:_
Methyl parahydroxybenzoate (E 218)
1.0 mg
Propyl parahydroxybenzoate
0.2 mg
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Solution for injection.
A clear colourless, sterile aqueous solution.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dog and Cat
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
_In dogs and cats:_
Sedation to facilitate handling. Premedication prior to general
anaesthesia.
_In cats:_
In combination with ketamine for general anaesthesia for minor
surgical procedures of short duration.
4.3 CONTRAINDICATIONS
Do not use in animals with:
-
severe cardiovascular disease or respiratory diseases or impaired
liver or kidney function.
-
mechanical disturbances of the gastrointestinal tract (torsio
ventriculi, incarcerations, oesophagal
obstructions).
-
pregnancy.
-
diabetes mellitus.
-
state of shock, emaciation or serious debilitation.
Do not use concomitantly with sympathomimetic amines.
Do not use in cases of known hypersensitivity to the active substance
or to any other excipients.
Do not use in animals with ocular problems where an increase in
intraocular pressure would be detrimental.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_